Iovance Biotherapeutics (IOVA) Competitors $2.23 -0.19 (-7.85%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$2.20 -0.02 (-1.12%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. PTGX, APLS, MLTX, MTSR, MIRM, MENS, KYMR, SRRK, BHC, and XENEShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Bausch Health Cos (BHC), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Protagonist Therapeutics Apellis Pharmaceuticals MoonLake Immunotherapeutics Metsera Mirum Pharmaceuticals Jyong Biotech Kymera Therapeutics Scholar Rock Bausch Health Cos Xenon Pharmaceuticals Protagonist Therapeutics (NASDAQ:PTGX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Do insiders and institutionals believe in PTGX or IOVA? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, PTGX or IOVA? Protagonist Therapeutics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Does the media refer more to PTGX or IOVA? In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 14 mentions for Iovance Biotherapeutics and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.48 beat Iovance Biotherapeutics' score of 0.90 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has stronger earnings & valuation, PTGX or IOVA? Protagonist Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M8.33$275.19M$0.7083.06Iovance Biotherapeutics$164.07M4.92-$372.18M-$1.23-1.81 Is PTGX or IOVA more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Iovance Biotherapeutics' net margin of -161.44%. Protagonist Therapeutics' return on equity of 8.12% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics24.88% 8.12% 7.41% Iovance Biotherapeutics -161.44%-52.87%-41.31% Do analysts recommend PTGX or IOVA? Protagonist Therapeutics currently has a consensus price target of $67.20, suggesting a potential upside of 15.58%. Iovance Biotherapeutics has a consensus price target of $11.90, suggesting a potential upside of 433.63%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Iovance Biotherapeutics 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36 SummaryProtagonist Therapeutics beats Iovance Biotherapeutics on 14 of the 17 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$875.69M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-1.8121.0831.2626.59Price / Sales4.92356.05436.91155.84Price / CashN/A44.6737.7359.36Price / Book1.168.0910.736.68Net Income-$372.18M-$54.08M$3.27B$265.59M7 Day Performance-17.10%-0.41%1.42%0.62%1 Month Performance-23.63%6.23%6.21%2.61%1 Year Performance-80.40%10.45%51.81%22.34% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.6068 of 5 stars$2.23-7.9%$11.90+433.6%-80.3%$875.69M$164.07M-1.81500PTGXProtagonist Therapeutics1.8839 of 5 stars$56.21+0.2%$67.20+19.6%+36.0%$3.50B$434.43M80.30120Positive NewsAPLSApellis Pharmaceuticals4.1452 of 5 stars$27.35-1.4%$34.12+24.7%-26.5%$3.45B$781.37M-15.03770MLTXMoonLake Immunotherapeutics1.813 of 5 stars$53.73-1.2%$74.43+38.5%+17.1%$3.45BN/A-19.332MTSRMetseraN/A$32.39+4.0%$55.00+69.8%N/A$3.40BN/A0.0081News CoveragePositive NewsAnalyst ForecastMIRMMirum Pharmaceuticals3.3071 of 5 stars$66.68-1.8%$74.13+11.2%+72.2%$3.35B$336.89M-55.11140Positive NewsMENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.16BN/A0.0031KYMRKymera Therapeutics3.093 of 5 stars$43.62+2.3%$59.11+35.5%-14.0%$3.12B$47.07M-12.57170Positive NewsSRRKScholar Rock4.5645 of 5 stars$31.52+0.4%$45.14+43.2%+268.1%$3.03B$33.19M-10.83140Positive NewsBHCBausch Health Cos4.7027 of 5 stars$8.02-3.8%$9.00+12.2%+21.5%$2.97B$9.63B30.8520,700XENEXenon Pharmaceuticals2.2996 of 5 stars$37.82-1.1%$53.20+40.7%-3.7%$2.92B$9.43M-10.65210Positive News Related Companies and Tools Related Companies Protagonist Therapeutics Competitors Apellis Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Metsera Competitors Mirum Pharmaceuticals Competitors Jyong Biotech Competitors Kymera Therapeutics Competitors Scholar Rock Competitors Bausch Health Cos Competitors Xenon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access